| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 113 | 2025 | 817 | 24.620 |
Why?
|
| Autoantibodies | 42 | 2025 | 435 | 7.400 |
Why?
|
| Diabetes Mellitus, Type 2 | 27 | 2024 | 1271 | 6.690 |
Why?
|
| C-Peptide | 25 | 2025 | 113 | 4.870 |
Why?
|
| Islets of Langerhans | 19 | 2024 | 174 | 4.640 |
Why?
|
| Insulin Resistance | 9 | 2024 | 641 | 3.220 |
Why?
|
| Insulin | 28 | 2025 | 1203 | 2.790 |
Why?
|
| Diabetic Ketoacidosis | 12 | 2024 | 160 | 2.420 |
Why?
|
| Blood Glucose | 21 | 2025 | 1131 | 2.320 |
Why?
|
| Autoimmunity | 13 | 2020 | 172 | 2.000 |
Why?
|
| Polymorphism, Single Nucleotide | 11 | 2025 | 2637 | 2.000 |
Why?
|
| Adolescent | 71 | 2025 | 19362 | 1.990 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 6 | 2022 | 24 | 1.860 |
Why?
|
| Genetic Predisposition to Disease | 21 | 2025 | 3157 | 1.830 |
Why?
|
| Hypoglycemic Agents | 12 | 2024 | 444 | 1.800 |
Why?
|
| Child | 75 | 2025 | 24418 | 1.750 |
Why?
|
| HLA-DQ Antigens | 7 | 2024 | 21 | 1.740 |
Why?
|
| Insulin-Secreting Cells | 7 | 2024 | 148 | 1.530 |
Why?
|
| Glucose Tolerance Test | 11 | 2025 | 208 | 1.450 |
Why?
|
| Humans | 137 | 2025 | 125186 | 1.390 |
Why?
|
| Diabetes Complications | 2 | 2023 | 203 | 1.300 |
Why?
|
| Child, Preschool | 43 | 2025 | 14026 | 1.250 |
Why?
|
| Genetic Heterogeneity | 3 | 2018 | 125 | 1.130 |
Why?
|
| Glutamate Decarboxylase | 6 | 2017 | 38 | 1.120 |
Why?
|
| Disease Progression | 20 | 2025 | 2067 | 1.110 |
Why?
|
| Male | 77 | 2025 | 61523 | 1.100 |
Why?
|
| Female | 78 | 2025 | 66803 | 1.070 |
Why?
|
| Young Adult | 25 | 2025 | 9053 | 0.970 |
Why?
|
| HLA-DR3 Antigen | 1 | 2024 | 1 | 0.950 |
Why?
|
| HLA-DR4 Antigen | 1 | 2024 | 6 | 0.950 |
Why?
|
| Hypoglycemia | 6 | 2018 | 190 | 0.910 |
Why?
|
| Body Mass Index | 10 | 2023 | 1565 | 0.910 |
Why?
|
| Immunoglobulin A | 2 | 2024 | 207 | 0.850 |
Why?
|
| Adult | 39 | 2025 | 29627 | 0.840 |
Why?
|
| Leptin | 2 | 2023 | 214 | 0.820 |
Why?
|
| Puberty | 2 | 2021 | 95 | 0.810 |
Why?
|
| Risk Factors | 23 | 2025 | 10316 | 0.810 |
Why?
|
| Minority Groups | 3 | 2020 | 249 | 0.780 |
Why?
|
| Biomarkers | 9 | 2024 | 3091 | 0.770 |
Why?
|
| Obesity | 10 | 2022 | 2248 | 0.770 |
Why?
|
| Infant | 24 | 2024 | 12514 | 0.750 |
Why?
|
| Pediatric Obesity | 5 | 2021 | 383 | 0.740 |
Why?
|
| Metformin | 1 | 2023 | 151 | 0.740 |
Why?
|
| Genetic Linkage | 2 | 2021 | 453 | 0.720 |
Why?
|
| Hyperglycemia | 4 | 2020 | 225 | 0.720 |
Why?
|
| Diabetes, Gestational | 1 | 2022 | 109 | 0.690 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 299 | 0.670 |
Why?
|
| Diagnostic Errors | 1 | 2024 | 334 | 0.670 |
Why?
|
| Cohort Studies | 17 | 2025 | 4817 | 0.610 |
Why?
|
| Overweight | 7 | 2020 | 364 | 0.600 |
Why?
|
| Flatfishes | 3 | 2006 | 3 | 0.580 |
Why?
|
| Age of Onset | 6 | 2020 | 595 | 0.580 |
Why?
|
| Fish Diseases | 3 | 2006 | 10 | 0.580 |
Why?
|
| Phenotype | 9 | 2024 | 4262 | 0.580 |
Why?
|
| Decision Support Techniques | 1 | 2021 | 290 | 0.570 |
Why?
|
| Prospective Studies | 15 | 2024 | 6153 | 0.560 |
Why?
|
| Adiposity | 2 | 2020 | 190 | 0.560 |
Why?
|
| Diabetes Mellitus | 4 | 2024 | 874 | 0.560 |
Why?
|
| Precision Medicine | 4 | 2024 | 319 | 0.560 |
Why?
|
| Osteocalcin | 1 | 2017 | 42 | 0.540 |
Why?
|
| Cross-Sectional Studies | 6 | 2024 | 3425 | 0.530 |
Why?
|
| Prognosis | 8 | 2024 | 4645 | 0.530 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 6 | 2025 | 11 | 0.530 |
Why?
|
| Protozoan Infections, Animal | 2 | 2006 | 3 | 0.520 |
Why?
|
| Prediabetic State | 3 | 2015 | 58 | 0.520 |
Why?
|
| Age Factors | 10 | 2024 | 2823 | 0.510 |
Why?
|
| Twins, Monozygotic | 3 | 2008 | 117 | 0.510 |
Why?
|
| Hospitalization | 1 | 2024 | 1783 | 0.500 |
Why?
|
| Diseases in Twins | 2 | 2008 | 94 | 0.470 |
Why?
|
| Thinness | 1 | 2014 | 70 | 0.440 |
Why?
|
| Insulin Infusion Systems | 4 | 2023 | 65 | 0.440 |
Why?
|
| Glucose | 5 | 2023 | 877 | 0.410 |
Why?
|
| Middle Aged | 20 | 2025 | 26928 | 0.400 |
Why?
|
| Haplotypes | 7 | 2024 | 522 | 0.390 |
Why?
|
| Health Personnel | 1 | 2017 | 507 | 0.390 |
Why?
|
| Family | 4 | 2025 | 566 | 0.380 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 667 | 0.370 |
Why?
|
| Blood Glucose Self-Monitoring | 4 | 2023 | 122 | 0.370 |
Why?
|
| Sex Factors | 6 | 2024 | 1289 | 0.360 |
Why?
|
| Retrospective Studies | 9 | 2025 | 16353 | 0.360 |
Why?
|
| Follow-Up Studies | 9 | 2024 | 5176 | 0.350 |
Why?
|
| Socioeconomic Factors | 5 | 2018 | 872 | 0.340 |
Why?
|
| Patient Preference | 1 | 2011 | 118 | 0.340 |
Why?
|
| Eukaryota | 2 | 2006 | 21 | 0.320 |
Why?
|
| Prevalence | 6 | 2024 | 2458 | 0.320 |
Why?
|
| Antibody Specificity | 3 | 2018 | 204 | 0.310 |
Why?
|
| Social Class | 3 | 2020 | 190 | 0.300 |
Why?
|
| Zinc Transporter 8 | 3 | 2017 | 6 | 0.300 |
Why?
|
| HLA Antigens | 3 | 2025 | 245 | 0.290 |
Why?
|
| Health Services Accessibility | 3 | 2020 | 606 | 0.280 |
Why?
|
| Twins, Dizygotic | 2 | 2004 | 42 | 0.270 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 2006 | 41 | 0.250 |
Why?
|
| Major Histocompatibility Complex | 4 | 2017 | 51 | 0.250 |
Why?
|
| Dyslipidemias | 2 | 2021 | 234 | 0.250 |
Why?
|
| Health Status Disparities | 2 | 2020 | 228 | 0.250 |
Why?
|
| Cluster Analysis | 2 | 2024 | 398 | 0.250 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 1970 | 0.250 |
Why?
|
| Social Determinants of Health | 2 | 2023 | 126 | 0.230 |
Why?
|
| Immunotherapy | 2 | 2024 | 680 | 0.220 |
Why?
|
| Cytokines | 3 | 2024 | 1288 | 0.220 |
Why?
|
| Alleles | 5 | 2017 | 1614 | 0.220 |
Why?
|
| Weight Gain | 3 | 2017 | 400 | 0.220 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 2 | 2022 | 62 | 0.220 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2022 | 69 | 0.220 |
Why?
|
| Siblings | 1 | 2004 | 196 | 0.220 |
Why?
|
| Immunity, Innate | 1 | 2006 | 372 | 0.210 |
Why?
|
| HLA-DRB1 Chains | 3 | 2017 | 38 | 0.210 |
Why?
|
| Genetic Vectors | 2 | 2017 | 940 | 0.210 |
Why?
|
| Fabaceae | 1 | 2023 | 24 | 0.210 |
Why?
|
| Genotype | 5 | 2018 | 2565 | 0.190 |
Why?
|
| Immune System | 2 | 2020 | 90 | 0.190 |
Why?
|
| Acanthosis Nigricans | 1 | 2022 | 10 | 0.190 |
Why?
|
| Self-Management | 2 | 2020 | 99 | 0.190 |
Why?
|
| HLA-DR Antigens | 2 | 2005 | 77 | 0.190 |
Why?
|
| Celiac Disease | 2 | 2017 | 67 | 0.190 |
Why?
|
| United States | 9 | 2020 | 10914 | 0.190 |
Why?
|
| Longitudinal Studies | 5 | 2025 | 1324 | 0.180 |
Why?
|
| Genetic Association Studies | 1 | 2025 | 779 | 0.180 |
Why?
|
| Sex Characteristics | 2 | 2020 | 313 | 0.180 |
Why?
|
| Latent Autoimmune Diabetes in Adults | 1 | 2020 | 2 | 0.180 |
Why?
|
| Interleukin-4 | 2 | 2005 | 140 | 0.180 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 511 | 0.170 |
Why?
|
| Early Diagnosis | 1 | 2021 | 183 | 0.170 |
Why?
|
| Healthcare Disparities | 2 | 2016 | 434 | 0.170 |
Why?
|
| HLA-DR2 Antigen | 1 | 1999 | 6 | 0.170 |
Why?
|
| Antibodies, Heterophile | 1 | 1999 | 10 | 0.170 |
Why?
|
| HLA-DQ alpha-Chains | 4 | 2017 | 17 | 0.170 |
Why?
|
| Genes, MHC Class II | 1 | 1999 | 33 | 0.170 |
Why?
|
| Biological Variation, Population | 1 | 2019 | 24 | 0.170 |
Why?
|
| Gene-Environment Interaction | 1 | 2020 | 122 | 0.160 |
Why?
|
| Autoimmune Diseases | 1 | 2002 | 251 | 0.160 |
Why?
|
| Spain | 5 | 2007 | 59 | 0.160 |
Why?
|
| Global Health | 1 | 2024 | 564 | 0.160 |
Why?
|
| Models, Immunological | 2 | 2015 | 36 | 0.160 |
Why?
|
| Chromosome Mapping | 1 | 2002 | 1078 | 0.160 |
Why?
|
| Prescription Drugs | 1 | 2020 | 54 | 0.160 |
Why?
|
| Cation Transport Proteins | 2 | 2017 | 93 | 0.150 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2018 | 13 | 0.150 |
Why?
|
| Mass Screening | 2 | 2022 | 784 | 0.150 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2020 | 171 | 0.150 |
Why?
|
| Registries | 4 | 2022 | 1435 | 0.150 |
Why?
|
| Electronic Health Records | 1 | 2024 | 722 | 0.140 |
Why?
|
| Area Under Curve | 3 | 2025 | 316 | 0.140 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 281 | 0.140 |
Why?
|
| Seasons | 3 | 2006 | 312 | 0.140 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 2174 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 259 | 0.140 |
Why?
|
| Leg | 1 | 1997 | 158 | 0.130 |
Why?
|
| Gene Frequency | 1 | 2018 | 724 | 0.130 |
Why?
|
| Pandemics | 1 | 2024 | 1107 | 0.130 |
Why?
|
| Communication | 2 | 2019 | 517 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2016 | 61 | 0.130 |
Why?
|
| Genetic Testing | 2 | 2017 | 1004 | 0.130 |
Why?
|
| Cultural Characteristics | 1 | 2016 | 41 | 0.130 |
Why?
|
| Retroviridae | 1 | 2016 | 198 | 0.130 |
Why?
|
| Exercise | 1 | 2022 | 816 | 0.130 |
Why?
|
| Glucagon | 1 | 2016 | 184 | 0.120 |
Why?
|
| Acculturation | 1 | 2016 | 68 | 0.120 |
Why?
|
| Histocompatibility Testing | 3 | 2001 | 148 | 0.120 |
Why?
|
| Perception | 1 | 2017 | 220 | 0.120 |
Why?
|
| Gastrointestinal Agents | 1 | 2016 | 62 | 0.120 |
Why?
|
| Time Factors | 5 | 2016 | 6336 | 0.120 |
Why?
|
| Nutritional Sciences | 1 | 2016 | 75 | 0.120 |
Why?
|
| Roma | 1 | 1995 | 4 | 0.120 |
Why?
|
| Lead Poisoning | 1 | 1995 | 5 | 0.120 |
Why?
|
| Child Development | 1 | 2017 | 266 | 0.120 |
Why?
|
| Health Literacy | 1 | 2016 | 80 | 0.120 |
Why?
|
| Diabetic Foot | 1 | 1997 | 163 | 0.120 |
Why?
|
| Cloning, Molecular | 1 | 2016 | 897 | 0.120 |
Why?
|
| Gene Transfer Techniques | 1 | 2016 | 357 | 0.120 |
Why?
|
| Stem Cell Transplantation | 1 | 2016 | 237 | 0.110 |
Why?
|
| Language | 1 | 2016 | 197 | 0.110 |
Why?
|
| Epitopes | 1 | 2016 | 433 | 0.110 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 144 | 0.110 |
Why?
|
| Qualitative Research | 1 | 2017 | 539 | 0.110 |
Why?
|
| Adipokines | 1 | 2014 | 59 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2017 | 482 | 0.110 |
Why?
|
| Polymorphism, Genetic | 4 | 2015 | 816 | 0.110 |
Why?
|
| Nuclear Family | 1 | 2013 | 49 | 0.110 |
Why?
|
| Inflammation | 1 | 2020 | 1446 | 0.100 |
Why?
|
| Lignans | 1 | 2012 | 3 | 0.100 |
Why?
|
| Infant, Newborn | 5 | 2020 | 8232 | 0.100 |
Why?
|
| Poverty | 1 | 2016 | 425 | 0.100 |
Why?
|
| Anticarcinogenic Agents | 1 | 2012 | 57 | 0.100 |
Why?
|
| Flavonoids | 1 | 2012 | 78 | 0.100 |
Why?
|
| Insulin Antibodies | 3 | 2017 | 7 | 0.100 |
Why?
|
| Pancreas, Artificial | 1 | 2011 | 2 | 0.090 |
Why?
|
| Self Administration | 1 | 2011 | 43 | 0.090 |
Why?
|
| Twin Studies as Topic | 2 | 2001 | 15 | 0.090 |
Why?
|
| Stem Cells | 1 | 2016 | 707 | 0.090 |
Why?
|
| Quality of Life | 1 | 2021 | 1934 | 0.090 |
Why?
|
| Alcohol Drinking | 1 | 2013 | 346 | 0.090 |
Why?
|
| Random Allocation | 2 | 2016 | 441 | 0.090 |
Why?
|
| Oxazolidinones | 2 | 2001 | 33 | 0.090 |
Why?
|
| Pedigree | 3 | 2021 | 1606 | 0.090 |
Why?
|
| Aging | 1 | 2017 | 1181 | 0.090 |
Why?
|
| Diet | 2 | 2012 | 1140 | 0.090 |
Why?
|
| Pregnancy | 1 | 2022 | 7207 | 0.080 |
Why?
|
| Aquaculture | 2 | 2006 | 6 | 0.080 |
Why?
|
| Animals | 10 | 2017 | 34230 | 0.080 |
Why?
|
| HLA-DQ beta-Chains | 2 | 2017 | 15 | 0.080 |
Why?
|
| Risk | 3 | 2017 | 756 | 0.080 |
Why?
|
| Autoantigens | 2 | 2001 | 118 | 0.080 |
Why?
|
| Incidence | 4 | 2013 | 3147 | 0.080 |
Why?
|
| Mental Disorders | 1 | 2016 | 828 | 0.080 |
Why?
|
| Proportional Hazards Models | 3 | 2013 | 1360 | 0.080 |
Why?
|
| Antigen-Presenting Cells | 2 | 2015 | 118 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 1726 | 0.070 |
Why?
|
| Body Weight | 2 | 2015 | 989 | 0.070 |
Why?
|
| Spleen | 2 | 2006 | 280 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2024 | 12392 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2023 | 1396 | 0.070 |
Why?
|
| Depression | 1 | 2015 | 1237 | 0.070 |
Why?
|
| Calpain | 1 | 2007 | 41 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 1438 | 0.070 |
Why?
|
| Stomach Neoplasms | 1 | 2012 | 548 | 0.070 |
Why?
|
| Hypertension | 1 | 2015 | 1330 | 0.070 |
Why?
|
| Immunity, Active | 1 | 2006 | 7 | 0.060 |
Why?
|
| alpha-Macroglobulins | 1 | 2006 | 6 | 0.060 |
Why?
|
| Laryngeal Neoplasms | 1 | 2007 | 84 | 0.060 |
Why?
|
| Life Tables | 1 | 2006 | 28 | 0.060 |
Why?
|
| Complement Pathway, Alternative | 1 | 2006 | 14 | 0.060 |
Why?
|
| Blood Cells | 1 | 2006 | 50 | 0.060 |
Why?
|
| Muramidase | 1 | 2006 | 94 | 0.060 |
Why?
|
| Granulocytes | 1 | 2006 | 65 | 0.060 |
Why?
|
| Pediatrics | 1 | 2015 | 1152 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2006 | 96 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 1026 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2006 | 142 | 0.060 |
Why?
|
| Case-Control Studies | 4 | 2017 | 3299 | 0.060 |
Why?
|
| Cryptosporidium | 1 | 2004 | 31 | 0.060 |
Why?
|
| Acetamides | 2 | 2001 | 47 | 0.060 |
Why?
|
| Family Health | 2 | 2005 | 259 | 0.060 |
Why?
|
| Drug Monitoring | 2 | 2016 | 170 | 0.050 |
Why?
|
| Racemethionine | 1 | 2023 | 6 | 0.050 |
Why?
|
| Mice, Inbred NOD | 3 | 2016 | 286 | 0.050 |
Why?
|
| Neoplasms | 2 | 2013 | 2790 | 0.050 |
Why?
|
| Aged | 6 | 2013 | 19871 | 0.050 |
Why?
|
| Methionine | 1 | 2023 | 102 | 0.050 |
Why?
|
| Liraglutide | 1 | 2022 | 14 | 0.050 |
Why?
|
| CTLA-4 Antigen | 2 | 2017 | 61 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2024 | 684 | 0.050 |
Why?
|
| Europe | 2 | 2013 | 354 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2006 | 1506 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 397 | 0.050 |
Why?
|
| Teicoplanin | 1 | 2001 | 4 | 0.050 |
Why?
|
| Coagulase | 1 | 2001 | 23 | 0.050 |
Why?
|
| Glutamine | 1 | 2023 | 215 | 0.050 |
Why?
|
| Citrulline | 1 | 2023 | 110 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2001 | 78 | 0.050 |
Why?
|
| Mesonephroma | 1 | 2001 | 1 | 0.050 |
Why?
|
| Papilloma | 1 | 2001 | 26 | 0.050 |
Why?
|
| Vaginal Neoplasms | 1 | 2001 | 15 | 0.050 |
Why?
|
| Methicillin Resistance | 1 | 2001 | 118 | 0.050 |
Why?
|
| Self Tolerance | 1 | 2001 | 5 | 0.050 |
Why?
|
| Thymus Gland | 1 | 2001 | 100 | 0.040 |
Why?
|
| Arginine | 1 | 2023 | 335 | 0.040 |
Why?
|
| Frameshift Mutation | 1 | 2021 | 180 | 0.040 |
Why?
|
| United Kingdom | 1 | 2001 | 190 | 0.040 |
Why?
|
| Aza Compounds | 1 | 2000 | 15 | 0.040 |
Why?
|
| Streptococcus | 1 | 2000 | 60 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 2001 | 221 | 0.040 |
Why?
|
| Consensus | 1 | 2023 | 641 | 0.040 |
Why?
|
| Body Composition | 2 | 2013 | 521 | 0.040 |
Why?
|
| Fluoroquinolones | 1 | 2000 | 93 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2023 | 634 | 0.040 |
Why?
|
| Quinolines | 1 | 2000 | 98 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 2 | 2001 | 2431 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 1115 | 0.040 |
Why?
|
| Kidney | 1 | 2006 | 1368 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2001 | 897 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 1172 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 569 | 0.040 |
Why?
|
| Artificial Limbs | 1 | 1997 | 7 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2001 | 462 | 0.040 |
Why?
|
| Pineal Gland | 1 | 1997 | 18 | 0.040 |
Why?
|
| Pinealoma | 1 | 1997 | 19 | 0.040 |
Why?
|
| Germinoma | 1 | 1997 | 30 | 0.040 |
Why?
|
| Models, Genetic | 1 | 2001 | 760 | 0.040 |
Why?
|
| Receptors, CCR7 | 1 | 2017 | 20 | 0.040 |
Why?
|
| Anthropometry | 1 | 2018 | 197 | 0.040 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 1998 | 77 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2020 | 324 | 0.040 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1997 | 70 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 1997 | 162 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2020 | 473 | 0.030 |
Why?
|
| Medical Records | 1 | 1997 | 192 | 0.030 |
Why?
|
| Pituitary Neoplasms | 1 | 1997 | 80 | 0.030 |
Why?
|
| Learning | 1 | 2020 | 361 | 0.030 |
Why?
|
| Comorbidity | 1 | 2022 | 1534 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2021 | 875 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2016 | 29 | 0.030 |
Why?
|
| Parenteral Nutrition | 1 | 1998 | 195 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 1999 | 777 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2016 | 130 | 0.030 |
Why?
|
| Cell Separation | 1 | 2016 | 229 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 1897 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2017 | 227 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2016 | 289 | 0.030 |
Why?
|
| Mice | 4 | 2017 | 17631 | 0.030 |
Why?
|
| Cell Line | 1 | 2000 | 2756 | 0.030 |
Why?
|
| DNA | 1 | 2000 | 1608 | 0.030 |
Why?
|
| Curriculum | 1 | 2020 | 726 | 0.030 |
Why?
|
| Rural Health | 1 | 1995 | 50 | 0.030 |
Why?
|
| Urban Health | 1 | 1995 | 78 | 0.030 |
Why?
|
| RNA, Long Noncoding | 1 | 2017 | 213 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 308 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2021 | 1502 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2016 | 186 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 3729 | 0.030 |
Why?
|
| Survival Rate | 1 | 1999 | 2062 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2015 | 139 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2017 | 558 | 0.030 |
Why?
|
| Transfection | 1 | 2016 | 1069 | 0.030 |
Why?
|
| Membrane Proteins | 2 | 2001 | 1527 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 733 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 1999 | 2057 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 553 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 1290 | 0.030 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2013 | 40 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2017 | 798 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2013 | 73 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2017 | 813 | 0.020 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 1995 | 136 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 472 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1696 | 0.020 |
Why?
|
| Length of Stay | 1 | 1997 | 1310 | 0.020 |
Why?
|
| Proteins | 1 | 2017 | 1036 | 0.020 |
Why?
|
| Cause of Death | 1 | 2013 | 476 | 0.020 |
Why?
|
| Linezolid | 2 | 2001 | 25 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1998 | 1251 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 2397 | 0.020 |
Why?
|
| Algorithms | 1 | 2017 | 1629 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 1056 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2012 | 471 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 2 | 2001 | 7 | 0.020 |
Why?
|
| Life Style | 1 | 2012 | 416 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 2048 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 1997 | 1216 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 2913 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 3465 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2017 | 2593 | 0.020 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2005 | 9 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 2005 | 61 | 0.020 |
Why?
|
| Israel | 1 | 2005 | 46 | 0.020 |
Why?
|
| Arabs | 1 | 2005 | 29 | 0.020 |
Why?
|
| Jews | 1 | 2005 | 32 | 0.020 |
Why?
|
| Atlantic Ocean | 1 | 2004 | 2 | 0.010 |
Why?
|
| Oocysts | 1 | 2004 | 3 | 0.010 |
Why?
|
| Interleukin-13 | 1 | 2005 | 97 | 0.010 |
Why?
|
| Histological Techniques | 1 | 2004 | 22 | 0.010 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2004 | 123 | 0.010 |
Why?
|
| Glutens | 1 | 2004 | 10 | 0.010 |
Why?
|
| Transglutaminases | 1 | 2004 | 24 | 0.010 |
Why?
|
| Species Specificity | 1 | 2004 | 550 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2005 | 432 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 1020 | 0.010 |
Why?
|
| Virus Diseases | 1 | 2005 | 280 | 0.010 |
Why?
|
| Denmark | 1 | 2001 | 33 | 0.010 |
Why?
|
| Clonal Deletion | 1 | 2001 | 2 | 0.010 |
Why?
|
| Proinsulin | 1 | 2001 | 12 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2001 | 258 | 0.010 |
Why?
|
| Virginiamycin | 1 | 2000 | 3 | 0.010 |
Why?
|
| Naphthyridines | 1 | 2000 | 7 | 0.010 |
Why?
|
| Erythromycin | 1 | 2000 | 20 | 0.010 |
Why?
|
| Oxazoles | 1 | 2000 | 23 | 0.010 |
Why?
|
| Epithelium | 1 | 2001 | 364 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 2000 | 194 | 0.010 |
Why?
|
| Vagina | 1 | 2001 | 185 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2004 | 778 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2001 | 410 | 0.010 |
Why?
|
| Environment | 1 | 2000 | 145 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2001 | 379 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2000 | 797 | 0.010 |
Why?
|
| Gene Expression | 1 | 2001 | 1560 | 0.010 |
Why?
|
| Triglycerides | 1 | 1998 | 575 | 0.010 |
Why?
|
| Apoptosis | 1 | 2001 | 1806 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2001 | 1497 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1997 | 3573 | 0.000 |
Why?
|